Literature DB >> 31173518

Protein and Peptide Biomaterials for Engineered Subunit Vaccines and Immunotherapeutic Applications.

Alexandra N Tsoras1, Julie A Champion1.   

Abstract

Although vaccines have been the primary defense against widespread infectious disease for decades, there is a critical need for improvement to combat complex and variable diseases. More control and specificity over the immune response can be achieved by using only subunit components in vaccines. However, these often lack sufficient immunogenicity to fully protect, and conjugation or carrier materials are required. A variety of protein and peptide biomaterials have improved effectiveness and delivery of subunit vaccines for infectious, cancer, and autoimmune diseases. They are biodegradable and have control over both material structure and immune function. Many of these materials are built from naturally occurring self-assembling proteins, which have been engineered for incorporation of vaccine components. In contrast, others are de novo designs of structures with immune function. In this review, protein biomaterial design, engineering, and immune functionality as vaccines or immunotherapies are discussed.

Entities:  

Keywords:  assembly; biomaterial; peptide; protein; vaccine

Mesh:

Substances:

Year:  2019        PMID: 31173518     DOI: 10.1146/annurev-chembioeng-060718-030347

Source DB:  PubMed          Journal:  Annu Rev Chem Biomol Eng        ISSN: 1947-5438            Impact factor:   11.059


  14 in total

1.  Designing a novel E2-IFN-γ fusion protein against CSFV by immunoinformatics and structural vaccinology approaches.

Authors:  Yanmin Zhang; Weijian Zhang; Jun Cheng; Xuping Liu; Shiwei Miao; Wen-Song Tan; Liang Zhao
Journal:  Appl Microbiol Biotechnol       Date:  2022-05-07       Impact factor: 4.813

2.  Tyrosine-Based Cross-Linking of Peptide Antigens to Generate Nanoclusters with Enhanced Immunogenicity: Demonstration Using the Conserved M2e Peptide of Influenza A.

Authors:  Logan R Wilks; Gaurav Joshi; Megan R Grisham; Harvinder Singh Gill
Journal:  ACS Infect Dis       Date:  2021-08-25       Impact factor: 5.578

Review 3.  The Versatile Manipulations of Self-Assembled Proteins in Vaccine Design.

Authors:  Que Dan Nguyen; Kosuke Kikuchi; Basudev Maity; Takafumi Ueno
Journal:  Int J Mol Sci       Date:  2021-02-16       Impact factor: 5.923

4.  Cooperating minimalist nanovaccine with PD-1 blockade for effective and feasible cancer immunotherapy.

Authors:  Mingxia Jiang; Liping Zhao; Xiaoming Cui; Xinghan Wu; Yuhan Zhang; Xiuwen Guan; Jinlong Ma; Weifen Zhang
Journal:  J Adv Res       Date:  2021-08-19       Impact factor: 10.479

5.  Genetically Engineered Cellular Membrane Vesicles as Tailorable Shells for Therapeutics.

Authors:  En Ren; Chao Liu; Peng Lv; Junqing Wang; Gang Liu
Journal:  Adv Sci (Weinh)       Date:  2021-09-08       Impact factor: 16.806

6.  Thermo-Viscoelastic Response of Protein-Based Hydrogels.

Authors:  Aleksey D Drozdov; Jesper deClaville Christiansen
Journal:  Bioengineering (Basel)       Date:  2021-05-31

7.  Rational Design of Antigen Incorporation Into Subunit Vaccine Biomaterials Can Enhance Antigen-Specific Immune Responses.

Authors:  Alexandra N Tsoras; Kong M Wong; Anant K Paravastu; Julie A Champion
Journal:  Front Immunol       Date:  2020-07-21       Impact factor: 7.561

8.  Interpretative immune targets and contemporary position for vaccine development against SARS-CoV-2: A systematic review.

Authors:  Nidhi Chauhan; Shringika Soni; Abhinandan Gupta; Mohammad Aslam; Utkarsh Jain
Journal:  J Med Virol       Date:  2020-12-17       Impact factor: 20.693

Review 9.  Advancements in prophylactic and therapeutic nanovaccines.

Authors:  Prateek Bhardwaj; Eshant Bhatia; Shivam Sharma; Nadim Ahamad; Rinti Banerjee
Journal:  Acta Biomater       Date:  2020-04-05       Impact factor: 10.633

Review 10.  SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants.

Authors:  Daniel Martínez-Flores; Jesús Zepeda-Cervantes; Adolfo Cruz-Reséndiz; Sergio Aguirre-Sampieri; Alicia Sampieri; Luis Vaca
Journal:  Front Immunol       Date:  2021-07-12       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.